The associations of systemic inflammation and insulin resistance-related indicators with psychopathology and BDNF in patients with chronic schizophrenia
Unequal voices: examining autism identification and diagnosis disparities for indigenous Mixtec families
Evaluation of anxiety levels and stress coping methods of pregnant women after the Kahramanmaraş earthquake
Correction: Development of a process model of posttraumatic growth in psychosis: a qualitative study
Plasma proteomic signature of the human menstrual cycle
Nature Medicine, Published online: 13 April 2026; doi:10.1038/s41591-026-04326-5
This Resource presents a large-scale analysis of nearly 3,000 circulating plasma proteins across the menstrual cycle in over 2,700 women from the UK Biobank, revealing distinct proteomic patterns across menstrual phases. This work sheds light on female reproductive biology and gynecological disorders, and provides a proteomic signature for accurate prediction of the menstrual cycle phase.
Why 2026 is the pivot point for electronic health records
STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy.
Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy.
It’s “very impressive,” said Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, in an email.
STAT+: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients
Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving the interim goal of an ongoing Phase 3 clinical trial.
While still preliminary, the new data bolster Allogene’s efforts to develop an easily administered cell therapy that, for the first time, could delay or prevent the recurrence of cancer in patients with a high risk of lymphoma relapse at the end of first-line treatment.
In the interim analysis, 58% of patients treated with the Allogene CAR-T, called cema-cel, achieved minimal residual disease, or MRD, negativity compared to 16% of patients who were observed but not treated.

